Drugs / CD19 Directed CAR T Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05535855 | Jan 2024 → Jun 2027 expected | acute lymphoblastic leukemia | University of Colorado, Denver | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 Directed CAR T Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05535855 ↗ |
| Modality | Cell therapy | “anti-CD19 chimeric antigen receptor-expressing (CAR) T cells” NCT05535855 ↗ |
| Target | CD19 | “anti-CD19 chimeric antigen receptor-expressing (CAR) T cells” NCT05535855 ↗ |